Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations
Open Access
- 25 November 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0313889
Abstract
Importance: Herpes zoster infection is common in immunocompromised individuals. Recently, the Advisory Committee on Immunization Practices recommended immunizing with the recombinant zoster vaccine (RZV). Objective: To evaluate the efficacy, immunogenicity and safety of RZV in immunocompromised individuals, such as transplant recipients, cancer patients undergoing chemotherapy, individuals with preexisting autoimmune diseases and HIV-infected patients. Data sources and selection: From January 1984 to October 2023, a systematic search of PubMed, MEDLINE, EMBASE, Scopus, Web of Science, CINAHL, and Cochrane CENTRAL was performed. Randomized clinical trials (RCT) evaluating RZV compared to placebo in immunocompromised adults were selected. Data extraction: Study characteristics and estimates on the incidence of herpes zoster, immune responses, and safety data were extracted from studies. Estimates were pooled using random-effects meta-analysis. Differences by study-level characteristics were estimated using subgroup meta-analysis and metaregression. Results: Seven RCTs were included. Compared to placebo, RZV reduced the incidence of herpes zoster across all ages by 81% (RR: 0.19, 95%CI: 0.09, 0.44), with moderate heterogeneity across the studies (I2 = 60.49%; τ2 = 0.31; P = 0.07). RZV significantly increased humoral and cellular immunity one month after the last dose. Transplant and past malignancy were associated with lower immunogenicity. RZV was more reactogenic with more local and systemic adverse events. There was no difference in serious adverse events or death between the two arms. Conclusion: This study suggests that RZV reduces the risk of herpes zoster infection in immunocompromised individuals. This vaccine should be routinely offered to immunocompromised individuals, preferably before chemotherapy or treatment.Keywords
This publication has 44 references indexed in Scilit:
- Diagnosis and Assessment of Pain Associated With Herpes Zoster and Postherpetic NeuralgiaThe Journal of Pain, 2008
- The Incidence of, Risk Factors for, and Sequelae of Herpes Zoster Among HIV Patients in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Aging, Immunity, and the Varicella–Zoster VirusNew England Journal of Medicine, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Varicella-zoster virus: Pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipientsTransplantation and Cellular Therapy, 2000
- Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantationBone Marrow Transplantation, 2000
- Clinical Spectrum of Herpes Zoster in Adults Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1995
- Infection with Varicella-Zoster Virus After Marrow TransplantationThe Journal of Infectious Diseases, 1985
- The Nature of Herpes Zoster: A Long-Term Study and a New HypothesisProceedings of the Royal Society of Medicine, 1965